Cycle Pharmaceuticals and Inceptua Group partner to provide free NITYR (nitisinone) tablets for hereditary tyrosinemia type 1 (HT1) and alcaptonuria (AKU) patients.
Cycle Pharmaceuticals Ltd and Inceptua Group announced a partnership to provide NITYR (nitisinone) tablets to eligible patients with hereditary tyrosinemia type 1 (HT-1) and alcaptonuria (AKU) under a free product access program.
CAMBRIDGE, R. U., 15 de enero de 2024. Cycle Pharmaceuticals Ltd (Cycle) e Inceptua Group (Inceptua) anunciaron una asociación para que NITYR (nitisinona) Tabletas esté disponible a través de un Programa de Productos Gratis para pacientes idóneos con tirosinemia hereditaria tipo 1 (TH-1) y alcaptonuria (ACU).
A presentation exploring how generics and biosimilars are affecting the MS treatment landscape, clinically proven risks, and the opportunities to navigate these.
Cycle Pharmaceuticals is looking for an enthusiastic and talented team player to join its fast-growing Sales Department as a Rare Disease Account Manager.
Cycle’s Executive Team includes accomplished leaders with deep and broad industry experience alongside entrepreneurial executives, defining new and exciting growth opportunities.